요폐 치료제 시장 보고서(2025년)

Urinary retention drugs are medications used to treat conditions where patients experience difficulty emptying the bladder, often by relaxing the bladder muscles or stimulating contractions in the bladder to help urine flow. These drugs are commonly prescribed for conditions such as benign prostatic hyperplasia (BPH) or neurogenic bladder, aiming to improve urinary function and relieve discomfort.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main drug classes for urinary retention include alpha blockers, beta-3 agonists, anticholinergics, and surgical agents. Alpha blockers are drugs that work by relaxing the bladder and prostate muscles, helping to improve urine flow and alleviate symptoms of BPH. These medications are used for conditions such as chronic urinary retention, postoperative urinary retention, and neurogenic bladder. They can be administered via oral, injectable, or transdermal routes and are prescribed in various settings, including hospitals, home care, specialty clinics, and others.

The urinary retention drug market research report is one of a series of new reports from The Business Research Company that provides urinary retention drug market statistics, including the urinary retention drug industry global market size, regional shares, competitors with the urinary retention drug market share, detailed urinary retention drug market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary retention drug industry. This urinary retention drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The urinary retention drug market size has grown strongly in recent years. It will grow from$3.87 billion in 2024 to $4.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historical period can be attributed to factors such as a rising aging population, increased healthcare investments, advancements in medical infrastructure, a growing geriatric demographic, a global increase in the elderly population, and a higher prevalence of BPH.

The urinary retention drug market size is expected to see strong growth in the next few years. It will grow to$5.21 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to factors such as the rising prevalence of urinary retention, an increase in postoperative urinary retention cases, a higher occurrence of urinary incontinence (UI), growing awareness of the benefits of early diagnosis and treatment, and the increasing prevalence of benign prostatic hyperplasia. Key trends in the forecast period include advancements in targeted drug delivery systems, drug formulations, artificial intelligence and machine learning, telemedicine and remote monitoring, as well as innovative solutions.

The growing prevalence of urinary disorders is expected to fuel the expansion of the urinary retention drug market. Urinary disorders are conditions that affect the urinary system, leading to issues such as difficulty urinating, pain, incontinence, or retention. The rise in these disorders is largely due to the increasing incidence of diabetes, as elevated blood sugar levels can damage the kidneys and urinary tract, resulting in conditions such as diabetic nephropathy and frequent urinary tract infections (UTIs). Urinary retention drugs help manage these conditions by improving urine flow, relaxing bladder muscles, and alleviating symptoms such as difficulty urinating, thus enhancing comfort and bladder function. For example, in October 2023, the National Health Service (NHS) in England reported 147,285 hospital admissions in 2022/23 with a primary diagnosis of urinary tract infection (UTI). Among these cases, individuals over the age of 65 represented 56%, totaling 82,392 admissions, with the highest number of cases occurring in the 80-84 age group (17,280 cases). This increasing prevalence of urinary disorders is driving the growth of the urinary retention drug market.

Key players in the urinary retention drug market are focusing on the development of innovative formulations such as extended-release tablets to improve patient compliance and offer prolonged symptom relief. Extended-release (ER) tablets are designed to release the active ingredient gradually over time, maintaining a consistent drug concentration in the bloodstream and reducing the need for frequent dosing compared to immediate-release tablets. For instance, in April 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched a generic version of Mirabegron for overactive bladder (OAB). Mirabegron, a selective beta-3 adrenergic agonist, relaxes bladder muscles to reduce urinary urgency, frequency, and incontinence. Although primarily used for OAB, it can also assist in managing urinary retention linked to overactive bladder conditions. The medication is administered as a once-daily oral dose.

In November 2024, Boston Scientific Corporation, a healthcare company based in the U.S., acquired Axonics Inc. for $3.3 billion. This acquisition allows Boston Scientific to expand its urology portfolio by integrating innovative technologies that address urinary and bowel dysfunction. Axonics Inc., a medical technology company based in the U.S., specializes in sacral neuromodulation (SNM) therapy for urinary control. This therapy is used to treat urinary retention and the symptoms of overactive bladder.

Major players in the urinary retention drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Ajanta Pharma Limited, Ferring Pharmaceuticals Inc., and UroGen Pharma Ltd.

North America was the largest region in the urinary retention drug market in 2024. The regions covered in urinary retention drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urinary retention drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary retention drugs market consist of sales of tamsulosin (flomax), bethanechol (urecholine), terazosin (hytrin), doxazosin (cardura), finasteride (proscar), and alfuzosin (uroxatral). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urinary Retention Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urinary retention drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urinary retention drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary retention drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Alpha Blockers; Beta-3 Agonists; Anticholinergics; Surgical Agents
• 2) By Indication: Chronic Urinary Retention; Postoperative Urinary Retention; Neurogenic Bladder
• 3) By Administration: Oral; Injectable; Transdermal
• 4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Alpha Blockers: Alpha-1 Blockers; Alpha-2 Blockers
• 2) By Beta-3 Agonists: Selective Beta-3 Agonists
• 3) By Anticholinergics: Antimuscarinics; Non-Selective Anticholinergics
• 4) By Surgical Agents: Anesthetics; Hemostatic Agents; Muscle Relaxants; Antibiotic Prophylaxis
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urinary Retention Drug Market Characteristics

3. Urinary Retention Drug Market Trends And Strategies

4. Urinary Retention Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Urinary Retention Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urinary Retention Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urinary Retention Drug Market Growth Rate Analysis
• 5.4. Global Urinary Retention Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urinary Retention Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urinary Retention Drug Total Addressable Market (TAM)

6. Urinary Retention Drug Market Segmentation

• 6.1. Global Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha Blockers
• Beta-3 Agonists
• Anticholinergics
• Surgical Agents
• 6.2. Global Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Urinary Retention
• Postoperative Urinary Retention
• Neurogenic Bladder
• 6.3. Global Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Transdermal
• 6.4. Global Urinary Retention Drug Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Urinary Retention Drug Market, Sub-Segmentation Of Alpha Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha-1 Blockers
• Alpha-2 Blockers
• 6.6. Global Urinary Retention Drug Market, Sub-Segmentation Of Beta-3 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Beta-3 Agonists
• 6.7. Global Urinary Retention Drug Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antimuscarinics
• Non-Selective Anticholinergics
• 6.8. Global Urinary Retention Drug Market, Sub-Segmentation Of Surgical Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anesthetics
• Hemostatic Agents
• Muscle Relaxants
• Antibiotic Prophylaxis

7. Urinary Retention Drug Market Regional And Country Analysis

• 7.1. Global Urinary Retention Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urinary Retention Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urinary Retention Drug Market

• 8.1. Asia-Pacific Urinary Retention Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urinary Retention Drug Market

• 9.1. China Urinary Retention Drug Market Overview
• 9.2. China Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urinary Retention Drug Market

• 10.1. India Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urinary Retention Drug Market

• 11.1. Japan Urinary Retention Drug Market Overview
• 11.2. Japan Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urinary Retention Drug Market

• 12.1. Australia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urinary Retention Drug Market

• 13.1. Indonesia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urinary Retention Drug Market

• 14.1. South Korea Urinary Retention Drug Market Overview
• 14.2. South Korea Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urinary Retention Drug Market

• 15.1. Western Europe Urinary Retention Drug Market Overview
• 15.2. Western Europe Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urinary Retention Drug Market

• 16.1. UK Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urinary Retention Drug Market

• 17.1. Germany Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urinary Retention Drug Market

• 18.1. France Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urinary Retention Drug Market

• 19.1. Italy Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urinary Retention Drug Market

• 20.1. Spain Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urinary Retention Drug Market

• 21.1. Eastern Europe Urinary Retention Drug Market Overview
• 21.2. Eastern Europe Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urinary Retention Drug Market

• 22.1. Russia Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urinary Retention Drug Market

• 23.1. North America Urinary Retention Drug Market Overview
• 23.2. North America Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urinary Retention Drug Market

• 24.1. USA Urinary Retention Drug Market Overview
• 24.2. USA Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urinary Retention Drug Market

• 25.1. Canada Urinary Retention Drug Market Overview
• 25.2. Canada Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urinary Retention Drug Market

• 26.1. South America Urinary Retention Drug Market Overview
• 26.2. South America Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urinary Retention Drug Market

• 27.1. Brazil Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urinary Retention Drug Market

• 28.1. Middle East Urinary Retention Drug Market Overview
• 28.2. Middle East Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urinary Retention Drug Market

• 29.1. Africa Urinary Retention Drug Market Overview
• 29.2. Africa Urinary Retention Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urinary Retention Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urinary Retention Drug Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urinary Retention Drug Market Competitive Landscape And Company Profiles

• 30.1. Urinary Retention Drug Market Competitive Landscape
• 30.2. Urinary Retention Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Urinary Retention Drug Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Novartis International AG
• 31.4. GlaxoSmithKline plc
• 31.5. Medtronic plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Teva Pharmaceutical Industries Limited
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Astellas Pharma Inc.
• 31.11. Sun Pharmaceutical Industries Limited
• 31.12. Aurobindo Pharma Limited
• 31.13. Lupin Limited
• 31.14. Cadila Healthcare Limited
• 31.15. Torrent Pharmaceuticals Limited

32. Global Urinary Retention Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urinary Retention Drug Market

34. Recent Developments In The Urinary Retention Drug Market

35. Urinary Retention Drug Market High Potential Countries, Segments and Strategies

• 35.1 Urinary Retention Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urinary Retention Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urinary Retention Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35004_Urinary_Retention_Drug_GMR_2025